Astromech has acquired Form Bio in an all-stock transaction valued at $230 million, combining evolutionary modeling with software for genetic medicine design and manufacturing optimization.
The transaction brings Form Bio’s employees, intellectual property, selected contracts, and other assets into Astromech.
Form Bio co-founder and former CEO Andrew Busey has become Astromech’s chief AI officer and head of technology.
Both companies originated within the Colossal Biosciences ecosystem.
Connecting Evolutionary Biology With Therapeutic Design
Astromech develops predictive models based on genomic and functional data collected across species and evolutionary periods.
The company uses deep learning and Bayesian reconstruction to study ancestral sequences, regulatory states, biological functions, and vulnerabilities.
DNA sequences preserved across millions of years can provide evidence about biological functions that may be important to living systems.
Form Bio develops foundation models and software for genomics, gene-therapy vector design, manufacturing analysis, and genomic quality assessment.
Combining the platforms is intended to help researchers move from identifying evolutionary patterns to creating genetic constructs that can be manufactured and tested.
The companies believe addressing unwanted components at the design stage could reduce downstream purification requirements.
Form Bio Supports Genetic Medicine Programs
Form Bio’s capabilities support programs at organizations including Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies, and Solid Biosciences.
In work with Cure Rare Disease involving Duchenne muscular dystrophy, Form Bio said promoter redesign increased full-genome content from 13% to 59% in less than 30 days. That program has moved into animal studies.
In another program, coding-sequence optimization increased full-genome content from approximately 2% to about 45% while maintaining baseline expression.
These examples are program-specific and do not establish clinical safety or effectiveness.
Form Bio launched in 2022 and raised more than $40 million before the acquisition. Astromech has raised more than $60 million.
The combined company plans to pursue applications in human therapeutics, genome engineering, and animal health.
KEY QUOTES:
Form Bio began by solving the computational challenges discovered from de-extinction and has grown into a company building foundation models for the design of human therapeutics. Our work with customers and partners has shaped that evolution, moving us from analyzing biological data to helping design genetic medicines. Joining Astromech gives us the opportunity to build on that progress, bringing evolutionary insights into the design decisions we help researchers make.
Andrew Busey, Chief AI Officer and Head of Technology at Astromech
Form Bio’s AI-driven design platform is helping us rapidly evaluate and prioritize gene therapy constructs across multiple programs.
Dr. Adrien Savy, Director of Discovery Science at Coave Therapeutics

